Drug Updates

Madrigal Pharmaceuticals Provides Corporate Update and Reports 202 Third Quarter Financial Results

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “Throughout the third quarter, the Madrigal team continued to progress MAESTRO-NASH, the pivotal serial liver biopsy study and a key component of the Phase 3 program for […]